title: Are HLA-DR or TAP genes genetic markers of severity in ulcerative colitis?
abstract: The pathogeny of ulcerative colitis (UC) is not yet elucidated, but some arguments suggest the implication of genetic factors. Among the candidate genes, those encoding for HLA class II genotypes have been extensively studied in UC; however, discordant data may be imputable to heterogeneity, characterized by immunological markers such as atypical ANCA (p-ANCA), or to inclusion of more or less intractable UC. The aim of our study is to evaluate the interest of HLA class II and TAP genetic markers to identify different clinical forms of UC, according to p-ANCA status. Unrelated patients with a history of UC (n = 91) and healthy control subjects with no personal or family history of inflammatory bowel diseases (IBD) (n = 200) were included. HLA-DRB1*03 was less frequent in UC patients than in healthy controls (8% vs 28%, PC < 0.03). No association was found with any TAP genotypes. Moreover, there was no association with the HLA-DR2 specificity, either in the entire group of UC patients (38% vs 28%) or in the p-ANCA-positive subgroup of patients (30%). The most consistent finding in the present study is that some genetic markers may characterize intractability in UC patients. HLA-DR2 was associated with poor prognosis, regardless of p-ANCA status. In HLA-DR2 and non-HLA-DR2 groups, colectomy was done in 55% and 27% of patients, respectively, (PC < 0.05). Furthermore, in non-HLA-DR2 patients, p-ANCA could be of interest to characterize those with more severe prognosis. Our results confirm the interest of genetic studies to define UC genetic susceptibility, taking into account intractability of the disease. They do not support the hypothesis that p-ANCA is a subclinical marker of genetic susceptibility to UC.
authors.affiliation: Service d'Hépato-Gastroentérologie, CHRU Pontchaillou, Rennes, France.
authors.forename: D
authors.initials: D
authors.lastname: Heresbach
authors.forename: M
authors.initials: M
authors.lastname: Alizadeh
authors.forename: D
authors.initials: D
authors.lastname: Reumaux
authors.forename: J F
authors.initials: JF
authors.lastname: Colombel
authors.forename: M
authors.initials: M
authors.lastname: Delamaire
authors.forename: P M
authors.initials: PM
authors.lastname: Danze
authors.forename: M
authors.initials: M
authors.lastname: Gosselin
authors.forename: B
authors.initials: B
authors.lastname: Genetet
authors.forename: J F
authors.initials: JF
authors.lastname: Bretagne
authors.forename: G
authors.initials: G
authors.lastname: Semana
mesh_terms: D000071181:ATP Binding Cassette Transporter, Subfamily B, Member 2; D000071450:ATP Binding Cassette Transporter, Subfamily B, Member 3; D018528:ATP-Binding Cassette Transporters / Q000235:genetics*; D000328:Adult; D000483:Alleles; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D016022:Case-Control Studies; D003093:Colitis, Ulcerative / Q000235:genetics* / Q000276:immunology*; D005260:Female; D005787:Gene Frequency; D005819:Genetic Markers; D005838:Genotype; D006684:HLA-DR Antigens / Q000235:genetics*; D006801:Humans; D008297:Male; D011379:Prognosis
chemical_list: D000071181:ATP Binding Cassette Transporter, Subfamily B, Member 2; D000071450:ATP Binding Cassette Transporter, Subfamily B, Member 3; D018528:ATP-Binding Cassette Transporters; D019268:Antibodies, Antineutrophil Cytoplasmic; D005819:Genetic Markers; D006684:HLA-DR Antigens; C073119:TAP1 protein, human; C071692:TAP2 protein, human